• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Precision BioSciences Inc.

    4/25/25 2:16:22 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DTIL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    PRECISION BIOSCIENCES INC

    (Name of Issuer)


    Common Stock, par value $0.000005 per share

    (Title of Class of Securities)


    74019P207

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74019P207


    1Names of Reporting Persons

    Highbridge Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    406,250.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    406,250.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    406,250.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  The 406,250 shares of Common Stock (as defined in Item 2(a)) reported herein are issuable upon exercise of warrants.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PRECISION BIOSCIENCES INC
    (b)Address of issuer's principal executive offices:

    302 East Pettigrew Street, Suite A-100, Durham, North Carolina 27701.
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of common stock, par value $0.000005 per share ("Common Stock"), of Precision BioSciences, Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.
    (c)Citizenship:

    Highbridge is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.000005 per share
    (e)CUSIP No.:

    74019P207
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 10,481,931 shares of Common Stock outstanding as of March 20, 2025, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on March 26, 2025, and assumes the exercise of the warrants held by the Highbridge Funds.
    (b)Percent of class:

    3.7%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Highbridge Capital Management, LLC
     
    Signature:/s/ Kirk Rule
    Name/Title:Kirk Rule, Executive Director
    Date:04/25/2025
    Get the next $DTIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DTIL

    DatePrice TargetRatingAnalyst
    1/10/2025$34.00Market Perform → Outperform
    BMO Capital Markets
    4/30/2024$19.00Buy
    Guggenheim
    6/17/2022$7.00Outperform
    BMO Capital Markets
    6/9/2022Outperform → Mkt Perform
    William Blair
    9/10/2021$23.00 → $26.00Buy
    Stifel
    More analyst ratings

    $DTIL
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

      - Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple in vivo gene editing programs; Expected cash runway into the second half of 2026 - Regained control of three advanced preclinical programs for development internally or with partners, including a novel gene editing approach for Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDA

      8/1/24 7:15:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

      Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural member of Precision's Hepatitis SAB, to provide counsel and deepen the Company's scientific and clinical expertise ahead of Precision's anticipated Investigational New Drug (IND) and/or Clinical Trial Application (CTA) submission of PBGE

      6/20/24 7:00:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Appoints Melinda Brown to Board of Directors

      New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202

      5/31/22 8:00:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Buehler Kevin bought $21,122 worth of shares (4,523 units at $4.67), increasing direct ownership by 52% to 13,235 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/28/25 7:02:15 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Brown Melinda bought $8,735 worth of shares (1,839 units at $4.75), increasing direct ownership by 25% to 9,057 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/28/25 7:00:04 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Germano Geno J bought $17,225 worth of shares (3,250 units at $5.30), increasing direct ownership by 42% to 11,057 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/27/25 7:00:04 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Precision BioSciences Inc.

      SCHEDULE 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

      5/15/25 4:15:23 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)

      5/15/25 8:00:20 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Precision BioSciences Inc.

      10-Q - PRECISION BIOSCIENCES INC (0001357874) (Filer)

      5/15/25 7:34:23 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DTIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DTIL
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $DTIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $DTIL
    Financials

    Live finance-specific insights

    See more

    $DTIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Precision BioSciences upgraded by BMO Capital Markets with a new price target

      BMO Capital Markets upgraded Precision BioSciences from Market Perform to Outperform and set a new price target of $34.00

      1/10/25 7:46:05 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Precision BioSciences with a new price target

      Guggenheim initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $19.00

      4/30/24 6:25:20 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Precision BioSciences with a new price target

      BMO Capital Markets initiated coverage of Precision BioSciences with a rating of Outperform and set a new price target of $7.00

      6/17/22 7:26:31 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

      - PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 - - Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time - - Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 - - Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing i

      5/14/25 4:30:00 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

      Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may ena

      5/8/25 7:01:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

      Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will present initial safety data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV program for the treatment of chronic hepatitis B during a late breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress being held May 7-10, 2025, in Amsterdam, Netherlands. "We are pleased to share initial safety data from the ELIMINATE-B trial for PBGENE-HBV at this year's EASL congress. Since initiating the trial, we have made rap

      5/7/25 7:01:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

      SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

      11/14/24 4:50:29 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

      SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

      11/14/24 4:00:06 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

      SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

      11/14/24 1:34:42 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

      - PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 - - Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time - - Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 - - Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing i

      5/14/25 4:30:00 PM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

      Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may ena

      5/8/25 7:01:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

      Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key

      3/21/25 7:01:00 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Buehler Kevin bought $21,122 worth of shares (4,523 units at $4.67), increasing direct ownership by 52% to 13,235 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/28/25 7:02:15 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Brown Melinda bought $8,735 worth of shares (1,839 units at $4.75), increasing direct ownership by 25% to 9,057 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/28/25 7:00:04 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Germano Geno J bought $17,225 worth of shares (3,250 units at $5.30), increasing direct ownership by 42% to 11,057 units (SEC Form 4)

      4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

      3/27/25 7:00:04 AM ET
      $DTIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care